Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy

NCT06586281 | Recruiting

• 1 other identifier: 809662
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients. Shared disease mechanisms may explain the increased severity in PsA. This study involves two visits from PsA patients with NAFLD and active disease signs (e.g., swollen joint, enthesitis, or psoriatic plaque). It aims to assess the impact of biological therapies on liver disorders, joints, and skin in PsA patients.

Conditions

Psoriatic Arthritis

Outcome Measures

Primary Outcomes (1)

• Change in NAFLD severity

  Defined by MRI-PDFF responders (relative change in liver fat ≥30%) vs non-responders (relative change in liver fat \<30%) at Week 24.

  24 weeks

Secondary Outcomes (3)

• Change from baseline in skin psoriasis severity

  24 weeks

• Change in joint arthritis

  24 weeks

• Change in ALT Levels

  24 weeks

Study Arms (1)

psoriatic arthritis patients

EXPERIMENTAL

Adults with active PsA and diagnosed NAFLD

Drug: Guselkumab

Interventions

Guselkumab DRUG

This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.

Also known as: Tremfya

psoriatic arthritis patients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults with diagnosis of PsA fulfilling the classification for PsA (CASPAR) criteria.
• Must have:
• or more swollen joint(s) and/or one or more active sites of enthesitis
• \. AND/OR
• or more psoriatic plaques
• \. No changes in the regular medication regimen within the last three months, and no use of systemic and/or chronic steroids within 8 weeks leading up to the study.
• \. Overweight or obese by BMI ≥ 25.0 kg/m2 or ≥ 23.0 for Asian participants
• \. Patients are starting Guselkumab therapy for PsA as indicated by primary rheumatologist

You may not qualify if:

• Patients with prior exposure to IL12/23i, IL-17i, JAKi, or TYK2i. Patients with exposure to more than 2 TNFi.
• Evidence of other causes of chronic liver disease
• Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).
• Previous or current infection with Hepatitis C as defined by presence of hepatitis C virus Abin serum (anti-HCV Ab).
• Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.
• Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.
• Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.
• Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.
• Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D.
• Drug-induced liver disease as defined on the basis of typical exposure and history.
• Bile duct obstruction as shown by imaging studies.
• History of gastrointestinal bypass surgery or ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, amiodarone or tetracycline in the previous 6 months.
• Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices
• Presence of regular and/or excessive use of alcohol (defined as \>30g/day for males and \>15g/day for females) for a period longer than 2 years at any times in the last 10 years
• Serum creatinine \> 2.0 mg/dL

Sponsors & Collaborators

• University of California, San Diego: lead
• Janssen Scientific Affairs, LLC: collaborator

Study Sites (1)

University of California, San Diego

San Diego, California, 92037, United States

RECRUITING

MeSH Terms

Conditions

Arthritis, Psoriatic

Interventions

guselkumab

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Monica Guma

CONTACT

8588226523; mguma@health.ucsd.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 29, 2024
• First Posted: September 19, 2024
• Study Start: June 1, 2025
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: June 10, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)